Study of AK138D1 alone or with ivonescimab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You have stage IIIB/IIIC or IV non-small cell lung cancer that has not been treated or has progressed.
- You are well enough to be up and about (ECOG score of 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your organs (like liver, kidneys, bone marrow) are working adequately.
- You do not have active cancer in the brain, active hepatitis B or C, active tuberculosis, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
This trial tests a new drug combination (YL201 and Ivonescimab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
This trial tests a new drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced breast cancer. The goal is to see if the treatment can shrink tumors or slow the cancer's growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.